18F-FDG PET/CT显像在肺动脉肉瘤患者中的临床应用价值
本研究回顾性分析14例肺动脉肉瘤(PAS)与33例肺血栓栓塞症(PTE)患者的临床、增强CT及18F-FDG PET/CT资料,PAS的SUVmax中位8.0(范围3.0-17.2)显著高于PTE的1.8(0.8-3.7)(P < 0.001),以2.9为界值诊断灵敏度100.0%、特异度93.9%;PAS中位总生存期10.5个月。
要点
- PAS的SUVmax中位8.0(范围3.0-17.2)显著高于PTE的1.8(0.8-3.7)(P < 0.001)。
- 以SUVmax 2.9为界值区分PAS与PTE,灵敏度100.0%、特异度93.9%。
- PAS中位总生存期10.5个月,12个月和24个月生存率分别为58.0%和12.0%。
核心结论
- 多数PAS表现为高糖代谢,18F-FDG PET/CT的SUVmax有助于区分PAS与PTE。
研究设计与样本
- 回顾性分析14例PAS患者与33例PTE患者的临床、增强CT和18F-FDG PET/CT特征。
- 在PAS患者中分析PET/CT代谢参数与临床及CT表现的相关性,并分析PAS患者的总生存期。
主要发现
- PAS的SUVmax中位8.0(范围3.0-17.2)显著高于PTE的1.8(0.8-3.7)(P < 0.001)。
- 以SUVmax 2.9为界值,区分PAS与PTE的灵敏度和特异度分别为100.0%和93.9%。
- 与PTE相比,PAS更多见于较年轻人群(P = 0.011),更多累及肺动脉干(P < 0.001),增强CT值(P < 0.001)及ΔCT(增强CT与非增强CT比较)(P < 0.001)更高。
- PAS的SUVmax与肿瘤分期(P = 0.022)、增强CT值(P = 0.013)及ΔCT值(P = 0.005)相关。
- PAS患者中位总生存期10.5个月,12个月和24个月生存率分别为58.0%和12.0%;仅D-二聚体水平(P = 0.038)和肿瘤分期(P = 0.019)与总生存期相关。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pulmonary artery sarcoma (PAS) is a rare and fatal malignancy. Due to the lack of specific clinical and radiological features, PAS is always misdiagnosed as pulmonary thromboembolism (PTE). This study aimed to investigate 18F-FDG PET/CT in distinguishing PAS from PTE, and analyze its correlation with clinical and radiological findings and outcome of PAS. METHODS: Clinical, contrast-enhanced CT, and 18F-FDG PET/CT characteristics of 14 patients with PAS and 33 patients with PTE were retrospectively reviewed. The correlation between PET/CT metabolic parameters vs. clinical and CT findings was investigated in patients with PAS. The overall survival (OS) was analyzed in PAS patients. RESULTS: The SUVmax of PAS (median: 8.0, range 3.0-17.2) was significantly higher than PTE (1.8[0.8-3.7]) (P < 0.001), and at a cutoff value of 2.9, the sensitivity and specificity were 100.0% and 93.9%, respectively. Compared with PTE, PAS more frequently occurred in younger population (P = 0.011), involved pulmonary trunk (P < 0.001), and displayed higher enhanced CT (P < 0.001) and ΔCT (enhanced CT compared to non-enhanced CT) (P < 0.001) values. SUVmax of PAS was associated with tumor staging (P = 0.022) and enhanced CT (P = 0.013) and ΔCT (P = 0.005) values. The median OS of PAS patients was 10.5 months, and 12-month and 24-month OS rates were 58.0% and 12.0%, respectively. Only D-dimer level (P = 0.038) and tumor staging (P = 0.019) were associated with OS. CONCLUSIONS: Most PAS displayed high glucometabolism, and SUVmax of 18F-FDG PET/CT was useful in distinguishing PAS from PTE.
引用
- Ren J, Li H, Zhang Q, et al. Clinical utility of 18F-FDG PET/CT imaging in patients with pulmonary artery sarcoma. EJNMMI Res. 2022. PMID: 35377010. doi:10.1186/s13550-022-00890-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。